- EQS-DD: MorphoSys AG: Dr. Marc Cluzel, buy
- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG Reports Outcome of Annual General Meeting 2023
- EQS-News: MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
- EQS-DD: MorphoSys AG: Charlotte Lohmann, Allocation of 157 shares as part of her remuneration as member of the Managing Board (Performance Share Plan 2019) (issuer's own shares)
- EQS-News: MorphoSys AG Reports First Quarter 2023 Financial Results
- EQS-News: Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
- EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
- EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
- EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 34.23m |
Free float | 33.66m |
P/E (TTM) | -- |
Market cap | 916.73m EUR |
EPS (TTM) | -2.14 EUR |
--
More ▼